Southport, CT - It is with a sense of both excitement and loss that we announce that one of our long standing partners, Gary Mathias, will be taking a leave of absence from his daily responsibilities at Carter Morse & Mathias to focus all of his energy on Thetis Pharmaceuticals, a drug discovery company founded in 2010 by the partners of CMM, former Pfizer executives and a nutraceutical client of CMM.
Thetis Pharmaceuticals is a biopharmaceutical company applying its HEALER™ technology to develop disease modifying agents targeting inflammation in gastrointestinal and respiratory diseases. Thetis is implementing this unique approach to capitalize on the strong evidence that the resolution of inflammation is not a passive process, but rather an active process regulated by endogenous proresolving mediators that are derived from Omega-3 and Omega-6 polyunsaturated fatty acids. Use of these mediators as immunoresolvent-based drugs to trigger the innate immune response to accelerate resolution represents an entirely new paradigm in the prevention and treatment of inflammatory disease that Thetis is pioneering in several disease areas.
Under Gary’s leadership as CEO, Thetis has raised more than $11 million of equity capital, recruited a team of world class scientific and clinical advisors, and established an impressive and growing patent portfolio. Thetis now has a growing pipeline of drug candidates that require Gary’s full time efforts. We are very excited for Gary and enthusiastic about the future of Thetis.
For nearly 15 years, Gary has been an invaluable partner at CMM where he has been instrumental in building our health care practice. He has had a profound influence on our firm and contributed to every element of our success over the years. His years of tireless effort, sound business judgement and strategic thinking have added significant value to both CMM and our clients.
All of us here at CMM wish Gary the best of luck and look forward to his return to CMM once Thetis realizes its full potential.